{"doi":"10.1007/s11095-022-03380-1","title":"Embracing Project Optimus: Can we Leverage Evolutionary Theory to Optimize Dosing in Oncology?","abstract":null,"journal":"Pharmaceutical Research","year":2022,"id":630550,"datarank":0.3453877639491069,"base_score":2.302585092994046,"endowment":2.302585092994046,"self_citation_contribution":0.3453877639491069,"citation_network_contribution":0.0,"self_endowment_contribution":0.3453877639491069,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":9,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":884563,"name":"Tyler Dunlap","orcid":"0000-0003-0385-9219","position":1,"is_corresponding":false},{"id":440083,"name":"Yanguang Cao","orcid":"0000-0002-3974-9073","position":2,"is_corresponding":false},{"id":1263792,"name":"Timothy Qi","orcid":"0009-0007-7323-0447","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Embracing Project Optimus: Can we Leverage Evolutionary Theory to Optimize Dosing in Oncology?","abstract":"Project Optimus is a US Food and Drug Administration (FDA) initiative to reform dose selection in oncology drug development. Here, we focus on tumor evolution, a broadly observed phenomenon that invariably leads to therapeutic failure and disease relapse, and its effect on the exposure-response (E-R) relationships of oncology drugs. We propose a greater emphasis on tumor evolution during clinical development to facilitate the selection of optimal doses for molecularly targeted therapies and immunotherapies in oncology.","is_dataset_classified":null,"base_score":2.302585092994046,"endowment":2.302585092994046,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"36056271","pmcid":"PMC9789176","openalex_id":"https://openalex.org/W4294316293","authors":[],"funders":[{"funder_name":"National Institute of General Medical Sciences","grant_id":"GM119661","title":null},{"funder_name":"NIGMS NIH HHS","grant_id":"R35 GM119661","title":null},{"funder_name":"National Institutes of Health","grant_id":"5R35GM119661-03","title":"Optimizing antibody-based therapy through a system platform of pharmacokinetics-pharmacodynamics-immunodynamics"}],"total_grants":3,"fwci":0.5887,"citation_percentile":0.60058732,"influential_citations":0,"citation_trend":[{"year":2022,"count":1},{"year":2023,"count":3},{"year":2024,"count":2},{"year":2025,"count":1},{"year":2026,"count":2}],"oa_status":"green","license":"Springer Nature TDM","oa_locations":[{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/9789176","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/9789176","host_type":"repository"},{"url":"https://link.springer.com/content/pdf/10.1007/s11095-022-03380-1.pdf","host_type":"publisher"},{"url":"https://link.springer.com/article/10.1007/s11095-022-03380-1/fulltext.html","host_type":"publisher"},{"url":"https://doi.org/10.1007/s11095-022-03380-1","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/36056271","host_type":"repository"},{"url":"https://dx.doi.org/10.17615/9wj5-m121","host_type":""}],"fields_of_study":["Cancer Genomics and Diagnostics","Mathematical Biology Tumor Growth","Evolution and Genetic Dynamics","0301 basic medicine","03 medical and health sciences","0302 clinical medicine","United States","Humans","Antineoplastic Agents","Neoplasms","Drug Development","Precision Medicine","Immunotherapy","United States Food and Drug Administration"],"mesh_terms":["Drug Development","Antineoplastic Agents","Humans","Immunotherapy","Neoplasms","United States","United States Food and Drug Administration","Precision Medicine"],"keywords":["Food and drug administration","Leverage (statistics)","Medicine","Dosing","Drug development","Oncology","Clinical Oncology","Selection (genetic algorithm)","Internal medicine","Drug","Intensive care medicine","Pharmacology","Cancer","Computer science","Precision Medicine","Tumor Evolution","United States Food and Drug Administration","Neoplasms","Humans","Antineoplastic Agents","Immunotherapy","United States"],"sdg_mappings":[{"sdg_number":3,"sdg_label":"3. Good health"},{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-05T21:37:58.563401Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}